Literature DB >> 19868979

SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREPTOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS : I. METHOD OF DEMONSTRATING PROTECTIVE ACTION OF IMMUNE SERA.

T M Rivers1.   

Abstract

Cultures of a hemolytic streptococcus isolated from a human case of erysipelas were tested for ability to produce lesions by injecting various amounts intradermally in shaved rabbits. Severe lesions could be developed at will in this way despite the fact that intravenous or intraperitoneal inoculations of large doses of the cultures failed to kill. The lesions were of two sorts, phlegmonous and erysipelas-like. A serum capable of warding off the injurious action of the streptococcus on the skin was procured from animals receiving repeated intracutaneous inoculations of the organism. Normal serum by contrast had no protective effect. By intradermal injections at several points in the same normal rabbit of small quantities of mixtures of equal parts of serum and various dilutions of a suspension of streptococci it proved possible to test sera for the presence of substances protective against the streptococcus.

Entities:  

Year:  1925        PMID: 19868979      PMCID: PMC2130937          DOI: 10.1084/jem.41.2.179

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  3 in total

1.  LOCAL PASSIVE IMMUNITY IN THE SKIN OF RABBITS TO INFECTION WITH (1) A FILTERABLE VIRUS, AND (2) HEMOLYTIC STREPTOCOCCI.

Authors:  T M Rivers; W S Tillett
Journal:  J Exp Med       Date:  1925-01-31       Impact factor: 14.307

2.  STUDIES ON A CERTAIN SPREADING FACTOR EXISTING IN BACTERIA AND ITS SIGNIFICANCE FOR BACTERIAL INVASIVENESS.

Authors:  F Duran-Reynals
Journal:  J Exp Med       Date:  1933-07-31       Impact factor: 14.307

3.  THE SKIN RESPONSE OF RABBITS TO NON-HEMOLYTIC STREPTOCOCCI : I. DESCRIPTION OF A SECONDARY REACTION OCCURRING LOCALLY AFTER INTRADERMAL INOCULATION.

Authors:  C H Andrewes; C L Derick; H F Swift
Journal:  J Exp Med       Date:  1926-06-30       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.